In addition to leading scholarship and inquiry in the form of peer-reviewed publications, CIIC researchers are dedicated to maximizing the translational impact of their work through the formation of startups.
The Polsky Center for Entrepreneurship & Innovation partners with CIIC researchers to patent their work and to identify programs and partners to support development of their discoveries.
CIIC researchers are leaders in their disciplines and publish regularly in the world’s most respected peer-reviewed journals. Our work is revealing new insights into the nature and behavior of the immune system in health and disease, and creating new diagnostics and therapeutics that will revolutionize tomorrow’s clinical practice. Our alumni are thought leaders in immunoengineering across academia and industry.
Founded by two of Prof. Jeffrey Hubbell’s Ph.D students, Anokion is changing the way we treat autoimmune diseases.
Instead of treating patients with drugs designed to suppress the whole immune system, Anokion is looking to train the immune system to tolerate, instead of attack the triggers that cause autoimmune inflammation. Since 2012, the company grew from four people co-habiting the Hubbell labs into its own separate space with currently 50 employees, raising US$40m in its Series B fundraising round.
Profs. Cathryn Nagler & Jeffrey Hubbell teamed up with John Colson via the Polsky Innovation Fund program to create ClostraBio.
Based off Profs. Nagler’s discoveries on mechanisms that lead to food allergies, ClostraBio is working to develop ways to augment the gastrointestinal microbiome, creating a barrier that prevents allergens such as peanuts from stimulating an allergic reaction.